BioSphere Medical Highlights Patient and Economic Benefits When Ob/Gyns and Interventional Radiologists Collaborate to Treat Women Suffering with Symptomatic Uterine Fibroids

BioSphere Medical, Inc. (NASDAQ: BSMD) today announced that more than 41,000 ob/gyns around the country are expected to receive a supplement in the April 2008 Contemporary OB/GYN which highlights the clinical benefits that result when ob/gyns and interventional radiologists (IRs) work in collaboration to treat women suffering with symptomatic uterine fibroids. The supplement, entitled "Expert Exchange: How to Formulate the Relationship Between the Ob/Gyn and the Interventional Radiologist for the Treatment of Uterine Fibroids,” was funded by BioSphere Medical. The "Expert Exchange” supplement details the mutually beneficial collaborative experiences of John H. Fischer II, M.D., Assistant Professor of Radiology, St. Luke’s Episcopal Hospital, Baylor College of Medicine, and Robert K. Zurawin, M.D., Associate Professor of Obstetrics and Gynecology, Baylor College of Medicine. These physicians discuss, among other things: the role of the gynecologist and interventional radiologist in counseling their patients on available treatment options, including minimally invasive uterine fibroid embolization (UFE), and surgical alternatives to conventional hysterectomy and myomectomy; the innovative patient algorithm they developed together to provide women with fibroids a thorough diagnostic assessment and comprehensive offering of individualized therapeutic options; their team approach to patient management, including clinical care responsibilities; and how their practice relationship has resulted in successful patient outcomes and increased patient referrals. Dr. Fischer and Dr. Zurawin agreed that their collaboration has allowed them to "…see many more patients than if we were not working with each other. By combining our resources and our expertise, we have a unique relationship that enables us to evaluate, treat, and help women with fibroids, regardless from whose practice they originate.” They continued, "…we are busier and more productive as a result of our collaboration. And at the end of the day, the patients receive better care.” Richard Faleschini, BioSphere Medical’s president and chief executive officer, said, "We strongly believe that good patient care and the economic interests of the key constituent providers are not mutually exclusive. In our experience, and as featured at this month’s Society of Interventional Radiology 33rd Annual Scientific Meeting, ob/gyns and IRs who forge successful relationships have the potential to optimize the quality of care provided to women suffering with symptomatic uterine fibroids and generate long-term economic benefits to both practices. Delivering this message directly to ob/gyns, who, in many cases, serve as the gatekeepers for women’s health care decisions, is a primary component of our overall strategy to accelerate the growth of UFE in the United States. I want to thank Dr. Fischer and Dr. Zurawin for sharing their experiences and providing thoughtful commentary on this important subject.” About BioSphere Medical, Inc. BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to develop and commercialize minimally invasive diagnostic and therapeutic applications based upon its pioneering proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties that are designed for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, the Company’s expectations regarding the expected benefits of its strategies aimed at growing UFE utilization, including through its promotion of the advantages of collaborative relationships between interventional radiologists and ob/gyn practitioners . The Company may use words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should," "intends," and similar expressions to identify these forward-looking statements. These statements are subject to risks and uncertainties and are based upon the Company's beliefs and assumptions. There are a number of important factors that may affect the Company's actual performance and results and the accuracy of its forward-looking statements, many of which are beyond the Company's control and are difficult to predict. These important factors include, without limitation, risks relating to: the failure of the Company’s products to demonstrate adequate safety, efficacy and cost-effectiveness in clinical trials, post-clearance studies and commercial use; the failure of the Company to successfully execute its sales and marketing strategies and/or to achieve widespread market acceptance of its products, including, without limitation, widespread market acceptance of its lead product, Embosphere® Microspheres, for the treatment of UFE, and its delivery system product line; the failure of the Company to achieve or maintain necessary regulatory approvals, either in the United States or internationally, with respect to the manufacture and sale of its products and product candidates; the failure of the Company to develop and commercialize new applications for its technologies; the Company's ability to obtain and maintain patent and other proprietary protection for its products and product candidates; the absence of, or delays and cancellations of, product orders; delays, difficulties or unanticipated costs in the introduction of new products; competitive pressures and the risk of product liability claims, either of which may impact market acceptance of products and adversely affect the Company's operating results; the inability of the Company to raise additional funds in the near term to finance the development, marketing, and sales of its products; general economic and market conditions; and statements set forth in the section titled "Risk Factors" in BioSphere’s Quarterly Report on Form 10-K for the quarter ended December 31, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company anticipates that subsequent events and developments may cause its forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances after the date of this press release.